

Serial no. 09/911,703

Attorney Docket no. 27693-01008

RECEIVED
CENTRAL FAX CENTER
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JAN 20 2006

Serial No.:	09/911,703	Group Art Unit:	1644
Confirmation No.:	4927	Examiner:	R. Schwadron
Filed:	25 July 2001		
Applicant:	Darrell R. ANDERSON et al.		
For:	Anti-CD20 Antibodies		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

POWER OF ATTORNEY BY ASSIGNEE AND CHANGE OF CORRESPONDENCE ADDRESS

The assignee of the entire right, title, and interest in U.S. patent application serial no. 09/911,703, Biogen Idec Inc., hereby revokes all previous powers of attorney in the above-identified application and appoints the practitioners associated with

CUSTOMER NUMBER 47553

as its attorneys and agents to prosecute the captioned patent application, and to transact all business in the U.S. Patent and Trademark Office connected therewith.

Direct all correspondence regarding this application to the address associated with **CUSTOMER NUMBER 47553**.

Please note the new attorney docket number for this application, **27693-01008**.

This application is a continuation of application serial no. 08/475,813, filed 07 June 1995, now U.S. Patent No. 6,682,734; which is a divisional of application serial no. 08/149,099, now U.S. Patent No. 5,736,137. Assignments of the '137 patent have effect as to this application. M.P.E.P. § 306.

Pursuant to 37 C.F.R. § 3.73(b), the undersigned states that Biogen Idec Inc. is the assignee of the entire right, title, and interest in the captioned application by virtue of the following assignments for U.S. Patent No. 5,736,137 recorded in the Patent and Trademark Office:

BI 0029 CP1C2

Serial no. 09/911,703

Attorney Docket no. 27693-01008

From the inventors
to IDEC Pharmaceuticals Corp.,

recorded at Reel 006850,
Frame 0468;

From IDEC Pharmaceuticals Corp.
to Merrill Lynch/Morgan Stanley Associates, L.P.,

Reel 007171,
Frame 0587;

From Merrill Lynch/Morgan Stanley Associates, L.P.
to IDEC Pharmaceuticals Corp.,

Reel 007934,
Frame 0284.

The following documents regarding the '137 patent are also recorded in the Office:

From IDEC Pharmaceuticals Corp.
in favor of Silicon Valley Bank as collateral agent
for Venture Lending & Leasing, Inc.,
granting a security interest,

recorded at Reel 007279,
Frame 0680;

From Venture Lending & Leasing, Inc.
in favor of IDEC Pharmaceuticals Corp.,
releasing all security interests,

Reel 010340,
Frame 0869.

Biogen Idec Inc. is the successor in interest to IDEC Pharmaceuticals Corp.

The undersigned, whose title is supplied below, is authorized to act on behalf of the assignee.

Respectfully submitted,



Christopher A. Dayton
Associate General Counsel, IP
Biogen Idec Inc.

8/22/05
Date

BI 0029 CP1C2